Drug Discovery and Development Strategies for COVID-19

Authors

  • Aarajana Shrestha College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea
  • Tara Man Kadayat Research Scientist, New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea

Keywords:

COVID-19, Drug Discovery and Development, Repurposed Drug

Abstract

Coronavirus Disease 2019 (COVID-19) has emerged as a global threat. Scientists and clinicians are endeavoring to find effective drugs and vaccines for this disease. This special issue of the Europasian Journal of Medical Sciences (EJMS) aims to cover the problems, solutions, and challenges of COVID-19 around the world. In this Editorial, EJMS Editors Aarajana Shrestha and Tara Man Kadayat highlight the processes of drug discovery and development and a brief overview of the current drug development strategies against COVID-19.

Downloads

Download data is not yet available.
Abstract
66
Download Full Text PDF
61

Author Biography

Aarajana Shrestha, College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea

Drug Discovery Researcher, Institute for Drug Research, Postdoctoral Research Program

Cover EJMS

Downloads

Published

2020-06-10

How to Cite

Shrestha, A., & Kadayat, T. M. (2020). Drug Discovery and Development Strategies for COVID-19. Europasian Journal of Medical Sciences, 2(4), 1–5. Retrieved from https://nepjol.info./index.php/ejms/article/view/33752

Issue

Vol. 2 (2020): Europasian Journal of Medical Sciences (EJMS)| COVID-19 Special Issue 4

Section

Editorial

License

Copyright (c) 2020 Author

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The author(s) retain the ownership of the copyrights for their work published in EJMS without any restrictions. Upon submission, the author(s) grants EJMS a license to publish, including to display, store, copy, and reuse the published content.

License to Publish
By submitting a manuscript to EJMS, the author(s) grant the journal a non-exclusive license to:

  • Publish and distribute the content in all formats, media, and platforms (both existing and future), while identifying EJMS as the original publisher.
  • Reproduce, display, and store the content in both print and online formats, including institutional and digital repositories.
  • Translate, adapt, and summarize the work, including reprints, extracts, and abstracts.
  • Develop derivative works based on the original content.
  • Include the work in electronic databases and provide links to third-party materials.

Creative Commons Licensing
In addition to EJMS’s publishing rights, authors grant third parties the right to use, share, and distribute their work under the Creative Commons Attribution 4.0 (CC BY 4.0) International License. This allows unrestricted use of the content, provided proper attribution is given to the original author(s) and the journal.